Endogenous relaxin-2 has been closely associated with a myriad of cardioprotective effects in the heart and blood vessels and has been proposed as a therapeutic strategy for several CVDs such as HF, atrial fibrillation (AF), acute myocardial infarction (AMI), ischemic heart disease, and hypertension [33]. The gene discussed is RLN2; the disease is myocardial infarction.